HEPALINK - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation as to its accuracy or completeness and expressly disclaims all or any liability arising out of or in connection with this announcement. assumes no responsibility for any loss arising from any part of the content or arising from reliance on such content.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (Shenzhen Hepalink Pharmaceutical Group Co., Ltd.) (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 9989)

Overseas regulatory announcement

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") pursuant to the Hong Kong Stock Exchange

made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Limited Company.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li Chairman

Shenzhen, China, March 30, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; The independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.

Securities code: 002399 Securities abbreviation: Hepalink Announcement number: 2026-007

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Announcement on applying for credit lines from banks and providing guarantees in 2026

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records.

information, misleading statements or material omissions.

Special tips:

1. The total amount of external guarantees provided by the company and its subsidiaries within the scope of consolidated statements in the next twelve months is expected to not exceed

RMB 10.09 billion, accounting for 83.87% of the company's audited net assets in the most recent year. Corporate and Consolidated Statements

There are no subsidiaries within the scope that provide guarantees for entities outside the scope of consolidation.

2. The company and its subsidiaries within the scope of consolidated statements are expected to have an asset-liability ratio exceeding 70% in the next twelve months.

The guarantee amount provided by the wholly-owned subsidiary is equivalent to no more than RMB 800 million, accounting for

6.65% of net assets.

Investors are advised to pay attention to guarantee risks.

1. Plans to apply for credit from banks and provide guarantees in 2026

In order to meet the requirements of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") and its wholly-owned subsidiaries

In order to meet the company's operation and business development needs, the company and its wholly-owned subsidiary Hepalink (Hong Kong) Co., Ltd. (hereinafter referred to as "Hong Kong"

"Ganghai Purui"), Shenzhen Tiandao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tiandao Pharmaceutical"), Tiandao Pharmaceutical (Hong Kong Hong Kong) Co., Ltd. (hereinafter referred to as "Tiandao Hong Kong"), SPL Acquisition Corp (hereinafter referred to as "SPL")

In 2026, we plan to apply for comprehensive credit lines (including renewal of expired credit) from various banks and financial institutions. In addition,

The company and its wholly-owned subsidiaries plan to provide guarantees to banks and financial institutions for part of the aforementioned credit lines.

(1) Proposed application for credit

As of the end of 2025, the company and its wholly-owned subsidiaries have obtained a total of credit facilities from banks and financial institutions equivalent to RMB

Approximately 15,497,861,400 yuan, and the actual usage amount is approximately 3,113,529,300 yuan. In 2026, the company and the whole The credit line (equivalent to RMB) that the subsidiary intends to apply for is expected to be as follows:

Credit amount Applicant Unit Purpose Credit Conditions Shareholding Ratio (10,000 yuan) Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trading companies and Tiandao Pharmaceuticals Company 800,000.00 Financing line, financing guarantee, purchase of raw materials, joint and several liability guarantee - materials, daily operating turnover, replacement of loans from other banks, and certificate guarantees Export bills, foreign exchange derivatives, etc. Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trade The company provides joint and several liability Hong Kong Hepalink 20,000.00 Financing line, financing guarantee, procurement of raw materials 100% Any guarantee materials, daily operating turnover, replacement of loans from other banks, Export bills, foreign exchange derivatives, etc. Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trade The company provides joint and several liability Tiandao Hong Kong 80,000.00 Financing line, financing guarantee, procurement of raw materials 100% Any guarantee materials, daily operating turnover, replacement of loans from other banks, Export bills, foreign exchange derivatives, etc. Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trade SPL own assets offset SPL 50,000.00 Financing line, financing guarantee, purchase of raw materials 100% charge materials, daily operating turnover, replacement of loans from other banks, Export bills, foreign exchange derivatives, etc. Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trade The company provides joint and several liability Tiandao Pharmaceutical 804,000.00 Financing line, financing guarantee, purchase of raw materials 100% Any guarantee materials, daily operating turnover, replacement of loans from other banks, Export bills, foreign exchange derivatives, etc. Medium and long-term fixed asset loans, medium and long-term current Capital loans, short-term working capital loans, trade Tiandao Pharmaceutical 100,000.00 Financing line, financing guarantee, purchase of raw materials Pure credit 100% materials, daily operating turnover, replacement of loans from other banks, Export bills, foreign exchange derivatives, etc. Total 1,854,000.00 - - - (2) Proposed guarantee In 2026, the company is a wholly-owned subsidiary and the wholly-owned subsidiary plans to provide the company with a guarantee amount equivalent to RMB Expect the following: Guarantee amount accounts for The secured party is currently most concerned about whether the plan for 2026 is Guarantors hold the most listed companies Guaranteed party Secured party Assets in the latest period Guarantee balance Amount of guarantee provided Related guarantee Share ratio Net capital in the latest period Debt ratio (10,000 yuan) Degree (10,000 yuan) Insurance Production ratio Company Hong Kong Hepalink 100% 61.71% - 20,000 1.66% No Company Tiandao Hong Kong 100% 91.37% 5,000.00 80,000 6.65% No Company Tiandao Pharmaceutical 100% 49.03% 204,924.54 804,000 66.83% No Tiandao Pharmaceutical Company Not applicable 19.59% 29,600.00 105,000 8.73% No

Total 239,524.54 1,009,000 83.87% No

The company's board of directors proposes to the shareholders' meeting to authorize the company's chairman to handle authorization from banks and financial institutions within the above quota.

Relevant procedures for credit business and guarantees, including but not limited to detailed negotiations with banks and financial institutions, signing relevant related agreements and procedures for applying for loans, equipment leasing, intellectual property asset securitization projects and financing activities; the same

The shareholders' meeting shall be submitted to authorize the chairman of the company to conduct business operations within the scope of the above-mentioned wholly-owned subsidiaries based on actual needs during the operation process.

The guarantee amount will be adjusted within the period, and the final total guarantee amount of the company and its wholly-owned subsidiaries in 2026 and the guarantee amount at any time point will be adjusted.

The balance of the guarantee will not exceed the guarantee amount granted this time, and the validity period will be from the 2025 annual shareholders' meeting to review and approve

One year from date.

The above matters have been unanimously approved by the 20th meeting of the company's sixth board of directors and still need to be submitted.

The company's 2025 annual shareholders' meeting reviewed and approved a special resolution.

2. Basic information of the guaranteed person

3. Company name: Shenzhen Tiandao Pharmaceutical Co., Ltd.

Unified social credit code: 91440300763486555H

Date of establishment: June 29, 2004

Registered address: No. 1, Rongtian South, Kengzi Street, Pingshan New District, Shenzhen City

Legal representative: Li Li

Registered capital: 768 million yuan

Main business: R&D, production and sales of enoxaparin sodium API and enoxaparin sodium preparations

Relationship with listed companies: Wholly owned subsidiary

Whether he is the person subject to execution for breach of trust: No

Major pending litigation, arbitration and other disputes: None

Main financial data in the past year:

Unit: Yuan Project 2025-12-31 Total assets 6,635,670,471.39 Total liabilities 3,253,691,623.37

Net assets 3,381,978,848.02 Asset-liability ratio 49.03% Current assets 5,974,073,328.25 Current liabilities 3,153,221,623.71 Project 2025 Operating income 3,534,047,595.55 Total profit 497,664,592.52

Net profit 422,511,617.91 2. Company name: Hepalink (Hong Kong) Co., Ltd.

Registration certificate number: 1531390

Date of establishment: November 23, 2010

Registered address: Room 4724, 47th Floor, Sun Hung Kai Center, 30 Harbor Road, Wan Chai, Hong Kong

Registered capital: HKD 330,221,400

Main business: import and export trade

Relationship with listed companies: Wholly owned subsidiary

Whether he is the person subject to execution for breach of trust: No

Major pending litigation, arbitration and other disputes: None

Main financial data in the past year:

Unit: Yuan Project 2025-12-31 Total assets 3,034,934,984.15 Total liabilities 1,872,810,407.01 Net assets 1,162,124,577.44 Asset-liability ratio 61.71%

Current assets 2,449,714,095.57 Current liabilities 1,868,314,242.65 Project 2025 Operating income 132,357,463.47 Total profit -45,427,924.34 Net profit -43,646,583.03

3. Company name: Tiandao Pharmaceutical (Hong Kong) Co., Ltd.

Registration certificate number: 1911197

Date of establishment: May 22, 2013

Registered address: 4th Floor, Yongsheng Commercial Center, 12-16 Wing Lok Street, Hong Kong

Registered capital: HKD 233.96 million

Main business: trade and import and export business, technology introduction and exchange

Relationship with listed companies: A wholly-owned subsidiary of Tiandao Pharmaceutical

Whether he is the person subject to execution for breach of trust: No

Major pending litigation, arbitration and other disputes: None

Main financial data in the past year:

Unit: Yuan Project 2025-12-31 Total assets 3,776,927,206.81 Total liabilities 3,450,129,078.53 Net assets 326,798,128.28

Asset-liability ratio 91.37% Current assets 3,715,987,893.56 Current liabilities 3,450,129,078.53 Project 2025 Operating income 2,027,072,310.62 Total profit -101,902,166.42 Net profit -101,874,394.29

4. Company name: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Unified social credit code: 91440300279544901A

Date of establishment: April 21, 1998

Registered address: No. 21, Langshan Road, Songpingshan, Nanshan District, Shenzhen

Legal representative: Li Li

Registered capital: 1,467,296,204 yuan

Main business: development, production and operation of raw materials (heparin sodium, enoxaparin sodium), engaged in goods and technology

Import and export (excluding distribution and state-owned, exclusively controlled, and monopolized goods); non-residential real estate leasing; housing leasing.

Relationship with Tiandao Pharmaceutical: Parent Company

Whether he is the person subject to execution for breach of trust: No

Major pending litigation, arbitration and other disputes: None

Main financial data in the past year:

Unit: Yuan Project 2025-12-31 Total assets 10,205,588,662.58 Total liabilities 1,999,728,414.61 Net assets 8,205,860,247.97

Asset-liability ratio 19.59% Current assets 4,815,386,251.45 Current liabilities 1,757,084,048.55 Project 2025 Operating income 2,178,756,728.65 Total profit -255,655,937.80 Net profit -203,049,684.51

3. Main contents of guarantee and credit agreement

The company and its wholly-owned subsidiaries plan to apply for comprehensive approval from banks and financial institutions under reasonable and fair contract terms. For credit business, the credit guarantee methods of banks and financial institutions are joint and several liability guarantees. The term and amount of each guarantee are

The amount is determined based on the loan contract signed after final negotiation between the company and its wholly-owned subsidiaries and relevant banks and financial institutions.

In the end, the total guarantee amount of the company and its wholly-owned subsidiaries in 2026 will not exceed the guarantee amount granted this time, and the validity period is

One year from the date of approval at the 2025 Annual Shareholders Meeting.

4. Opinions of the Board of Directors

The company's board of directors believes that the company and its wholly-owned subsidiaries will apply for credit lines from banks and financial institutions in 2026

The guarantee provided by Duji is to meet the company's overall operation and business development needs. Tiandao Pharmaceutical, Tiandao Hong Kong,

Hong Kong Hepalink is a wholly-owned subsidiary of the company. The company and its wholly-owned subsidiaries will apply to banks and financial institutions in 2026.

Please ensure that the risks of credit lines and guarantees are controllable, in line with the company's overall interests, and will not affect the company's normal operations.

adversely affect business development. The company applies for credit lines for its wholly-owned subsidiaries through guarantees to raise funds. The funds required for business development are in the interests of the company. Although the above-mentioned wholly-owned subsidiaries have not provided counter guarantees, the company

The company has absolute control over it, and the risks are all under the effective control of the company, which will not bring major risks to the company.

There is no harm to the interests of the company and all shareholders, especially small and medium shareholders. At the same time, Tiandao Pharmaceutical applied for the company’s

Please provide a joint liability guarantee for credit, which will help support the company's business development. Tiandao Pharmaceutical is in good operating condition.

It has the ability to perform contracts and the guarantee risks are controllable. The board of directors agreed to this matter and agreed to submit the matter to the public reviewed by the company’s shareholders’ meeting.

5. Cumulative number of external guarantees and number of overdue guarantees

As of the disclosure date of this announcement, the actual guarantee balance of the company and its subsidiaries within the scope of the consolidated statements is RMB

2,395,245,400 yuan, accounting for 19.91% of the company’s audited net assets in the most recent year. This guarantee matter was approved by the shareholders’ meeting

After review and approval, the company and its subsidiaries within the scope of the consolidated statements are expected to provide total external guarantees in the next twelve months equivalent to Not exceeding RMB 10.09 billion, accounting for 83.87% of the company's audited net assets in the most recent year. company and

There are no subsidiaries within the scope of the consolidated statements that provide guarantees for entities outside the scope of consolidation or that are overdue or involved in litigation.

guarantee situation.

6. Documents available for inspection

7. Resolution of the 20th meeting of the 6th Board of Directors

Announcement is hereby made.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

board of directors

March 31, 2026